Scientific Sessions 2025  /  Contemporary Controversies in Cardiac Transplantation and Circulatory Support Devices  /  The Best Method of DCD Organ Procurement is Direct Procurement Followed by Ex Vivo Perfusion.
Logo

American Heart Association

  68
  0

Final ID:

The Best Method of DCD Organ Procurement is Direct Procurement Followed by Ex Vivo Perfusion.

  • Dimarakis, Ioannis  ( University of Washington , Seattle , Washington , United States )
  • Pal, Jay  ( University of Washington , Seattle , Washington , United States )
  • Schroder, Jacob  ( DUKE UNIVERSITY MEDICAL CENTER , Durham , North Carolina , United States )
  • D'alessandro, David  ( Massacusetts General Hospital , Boston , Massachusetts , United States )
  • Fiedler, Amy  ( UCSF , San Francisco , California , United States )
  • Hayward, Chris  ( St Vincents , Darlinghurst , New South Wales , Australia )
    • Author Disclosures:
    Ioannis Dimarakis: DO NOT have relevant financial relationships | Jay Pal: No Answer | Jacob Schroder: No Answer | David D'Alessandro: No Answer | Amy Fiedler: DO NOT have relevant financial relationships | Chris Hayward: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Contemporary Controversies in Cardiac Transplantation and Circulatory Support Devices

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
A 50yo Veteran with PTSD has inotrope-dependent HF from long-standing ischemic cardiomyopathy, currently smokes 1ppd (down from 2ppd), and is AB blood type. The next best treatment is Cardiac Transplant.

Peters Laura, Mcilvennan Colleen, Sailer Christine, Ambardekar Amrut

A 75yo has inotrope-dependent HF. The best treatment is durable LVAD

Thomas Sunu, Sutaria Nilay, Zalawadiya Sandip

More abstracts from these authors:
Demonstration: LVAD insertion into Pig Heart

Sanchez Pablo, Fiedler Amy

Debate Pro:ECMO as a Bridge to Cardiac Transplant
In the current allocation system for cardiac transplant, patients supported by ECMO benefit from the highest priority on the wait-list. Even if a patient has some myocardial recovery, are they prognostically advantaged to go to transplant rather than to live with HFrEF.

Fiedler Amy, Elliott Andrea

You have to be authorized to contact abstract author. Please, Login
Not Available